Recent advances on the development of wound dressings for diabetic foot ulcer treatment—A review

Liane I.F. Moura a, b, Ana M.A. Dias b, Eugénia Carvalho a, c, * , Hermínio C. de Sousa b, * 

a Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal
b CIEPQF, Chemical Engineering Department, FCTUC, University of Coimbra, Rua Silvio Lima, Polo II – Pinhal de Marrocos, 3030-790 Coimbra, Portugal
* APDP, The Portuguese Diabetes Association, Rua do Salitre, No. 118-120, 1250-203 Lisboa, Portugal

A R T I C L E   I N F O

Article history:
Received 14 November 2012
Received in revised form 6 March 2013
Accepted 21 March 2013
Available online 27 March 2013

Keywords:
Diabetes
Diabetic foot ulcers
Wound healing
Wound dressings
Natural and synthetic polymers

A B S T R A C T

Diabetic foot ulcers (DFUs) are a chronic, non-healing complication of diabetes that lead to high hospital costs and, in extreme cases, to amputation. Diabetic neuropathy, peripheral vascular disease, abnormal cellular and cytokine/chemokine activity are among the main factors that hinder diabetic wound repair. DFUs represent a current and important challenge in the development of novel and efficient wound dressings. In general, an ideal wound dressing should provide a moist wound environment, offer protection from secondary infections, remove wound exudate and promote tissue regeneration. However, no existing dressing fulfills all the requirements associated with DFU treatment and the choice of the correct dressing depends on the wound type and stage, injury extension, patient condition and the tissues involved. Currently, there are different types of commercially available wound dressings that can be used for DFU treatment which differ on their application modes, materials, shape and on the methods involved. Moreover, wound dressings may be employed as medicated systems, through the delivery of healing enhancers and therapeutic substances (drugs, growth factors, peptides, stem cells and/or other bioactive substances). This work reviews the state of the art and the most recent advances in the development of wound dressings for DFU treatment. Special emphasis is given to systems employing new polymeric biomaterials, and to the latest and innovative therapeutic strategies and delivery approaches.

© 2013 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

1. Introduction

Diabetes mellitus is one of the most prevalent chronic diseases: in 2010, it was estimated that 285 million adults worldwide had diabetes and this figure is expected to rise to 439 million by 2030 [1,2]. In North America and Europe, the number of adults with diabetes is expected to increase by 42.4% and 20%, respectively, and a major burst in Africa is predicted, with the number of adults with diabetes expected to increase by 42.4% and 20%, respectively, and a major burst in Africa is predicted, with the number of adults with diabetes expected to increase by 42.4% and 20%, respectively. In 2000, the World Health Organization (WHO) estimated that 170 million adults were experiencing impaired glucose intolerance, which is first diagnosed during pregnancy. Gestational diabetes affects approximately 14% of pregnancies and type 1, type 2 and gestational diabetes. Type 1, insulin-dependent diabetes mellitus (IDDM), or juvenile-onset diabetes, is characterized by pancreatic β-cell destruction, leading to absolute insulin deficiency and, consequently, to the total dependence on exogenous insulin to sustain life [4,5]. The incidence of type 1 diabetes is usually higher under the age of 15 though only 20-50% of patients are diagnosed before this age. In addition, the Caucasian population tends to present a higher risk for type 1 diabetes when compared to all other ethnic groups [6]. Type 2 diabetes mellitus, also known as non-insulin-dependent diabetes mellitus (NIDDM), or adult-onset diabetes, is characterized by insulin resistance which may be combined with relatively reduced insulin secretion levels. Type 2 diabetes affects approximately 90% of all diabetic patients and its main risk factors are high plasma glucose concentrations in the fasting state and after an oral glucose load, being overweight and a sedentary lifestyle [7]. However, this type of diabetes can be delayed or prevented by a proper nutrition regime and by regular physical exercise [8,9]. Finally, gestational diabetes or impaired glucose intolerance, which is first diagnosed during pregnancy, is defined as carbohydrate intolerance during gestation [10]. Gestational diabetes affects approximately 14% of pregnancies and...
is also an important risk factor for type 2 diabetes in women [11,12].

In addition and among other problems, diabetic patients are more likely to develop obesity [13–16], coronary heart disease, stroke [17–19], diabetic nephropathy [20–23], diabetic retinopathy [24–27] and diabetic nephropathy [28–31]. These diseases are largely responsible for the observed high mortality rates in diabetic patients.

2. Diabetic foot ulcers (DFUs) and impaired wound healing

Wound healing is a complex process that involves the simultaneous actuation of soluble mediators, blood cells, extracellular matrix (ECM) and parenchymal cells. This process can be divided into several phases: homeostasis/coagulation, inflammation, proliferation (granulation tissue formation), re-epithelialization and remodeling [32,33]. These phases are not typically associated with a rigorous and well-defined period of time and may overlap [30,34–36]. The transition between phases usually depends on the maturation and differentiation of keratinocytes, fibroblasts, mast cells and macrophages which are the most important cells involved in the wound healing process [37–39].

After tissue injury, a fibrin plug is formed in order to re-establish homeostasis, and aggregated platelets secrete several growth factors and cytokines (e.g. transforming growth factor beta (TGF-β) and monocyte chemoattractant protein 1 (MCP-1)) that recruit neutrophils and monocytes to the wound site. These inflammatory cells induce the expression of colony-stimulating factor 1 (CSF-1), tumor necrosis factor α (TNF-α) and platelet-derived growth factor (PDGF) which are extremely important for the first phase of new tissue formation process [40,41]. Re-epithelialization usually begins a few hours after injury. In response to these growth factors, keratinocytes and activated fibroblasts migrate from the wound edges into the wound site where they proliferate and construct the ECM that will enhance wound closure [30,32]. The initial ECM is gradually replaced by a collagenous matrix with the formation of new blood vessels (angiogenesis) [38]. The angiogenic factors, such as fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF) and PDGF induce angiogenesis by stimulating the production of basic fibroblast and of vascular endothelial growth factors by macrophages and endothelial cells [40,42]. Protease expression and activity are also necessary for the angiogenesis process [38,42]. When the wound area is completely filled with new granulation tissue, angiogenesis stops and the apoptosis of many new vessels is then started. The last phase of the wound healing process is characterized by the degradation of the previously formed granulation tissue and by dermis regeneration [39]. While acute wounds usually progress linearly through the different wound healing phases, the healing process in diabetic patients does not follow this timeline, but rather results in chronic non-healing wounds that become stalled in one or more of the above-mentioned healing phases [35,43].

Chronic diabetic neuropathy, defined as temporary or permanent nerve tissue damage, is a common complication of diabetes which is characterized by a progressive loss of peripheral nerve fibers that is caused by a decreased blood flow and high glycemic levels [29,44]. The duration and intensity of the exposure to hyperglycemia strongly influences the severity of neuropathy [29]. Diabetic neuropathy can be classified as peripheral, autonomic, proximal or focal, depending on the affected body part [45,46]. It occurs in both type 1 and type 2 diabetes and is more frequent in older people. However, many diabetic patients may never develop neuropathy while others may develop this condition rather early [46,47]. On average, neuropathy symptoms begin to appear within 10–20 years of the diagnosis of diabetes, and approximately 50% of diabetic patients will develop nerve damage in some extent [48].

Diabetic neuropathy and peripheral vascular disease are usually the major factors involved in DFUs. These two factors may act alone, together, or in combination with other conditions such as microvascular disease, biomechanical abnormalities, limited joint mobility and increased susceptibility to infection [48,49]. Some studies report that the difficulties associated with DFU healing are mostly due to the excessive and persistent activity of metalloproteinases (MMPs) and/or due to low levels of MMP inhibitors [50,51]. In addition, ischemia and vascular disease usually reduce the healing capacity due to the reduced supply of oxygen and nutrients to the wound area [52]. There are also impaired granulocytic, chemotaxis and macrophage functions, as well as prolonged inflammation and deregulation of the neovascularization phase [53,54]. These issues are mainly due to impaired expression of growth and angiogenic factors, namely VEGF and PDGF [55]. Finally, there may also be nitric oxide abnormalities, collagen accumulation [56], abnormal migration and proliferation of fibroblasts and of keratinocytes [55], as well as accumulation of ECM components and their remodelling by MMPs [57]. Fig. 2 schematizes the phases and growth factors involved in diabetic wound healing processes in comparison with a regular wound.

In general, these chronic, non-healing neuropathic foot ulcers occur in around 15% of all the diabetic population [56] and are responsible for huge medical costs as well as significantly affecting patients’ quality of life [35,56,58]. Once a DFU has developed there is an increased risk of wound progression that may ultimately lead to amputation (more than 85% of foot amputations in patients are caused by DFU) [49].

The medical treatment of DFU remains a challenge. A better understanding of the pathophysiology and molecular biology of diabetic wounds may help to find improved and more efficient solutions for their treatment. It is currently accepted that DFU therapies should be directed to actively promoting wound healing by correcting the expression of those biological factors which are important in the healing process [59]. Table 1 describes some of the most recent approaches that have been used to stimulate DFU healing. However, to date, their efficacies and/or their application mode have not been sufficient to guarantee adequate DFU healing.

Like for acute wounds, it is already well established that to enhance DFU healing processes, wounds should be dressed with adequate biomaterials in order to protect the long-term healing from contamination/infection, to prevent wound dissection (providing an ideal moist environment to help wound closure) and, in the case of medicated dressings, to provide a sustained and effective release of the applied bioactive substances, as well as to prevent their rapid degradation during the healing process [60,61].

DFUs can be medically classified in a variety of ways but all of them define the ulcer in terms of its depth and the presence of osteomyelitis or gangrene [62,63]. As an example, the classification according to Wagner’s system is based on the following grades:
Fig. 2. Differences in the normal and diabetic wound healing phases (adapted from Beanes et al. 2003).
<table>
<thead>
<tr>
<th>Bioactive substances</th>
<th>Models used</th>
<th>Results</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Growth factors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VEGF</td>
<td>db/db diabetic mice</td>
<td>Enhanced neovascularization, mobilization of bone marrow-derived cells into the wound site to accelerate wound healing</td>
<td>Galiano et al, 2004 [257]</td>
</tr>
<tr>
<td>PDGF</td>
<td>STZ diabetic rats</td>
<td>Enhanced angiogenesis, cell proliferation and epithelialization. Formed thicker and more highly organized collagen fiber deposition</td>
<td>Li et al, 2008 [258]</td>
</tr>
<tr>
<td>bFGF</td>
<td>Human patients with DFUs</td>
<td>Reduction of 75% of wound area in treated patients. Stimulated granulation and epithelization of tissues</td>
<td>Uchi et al, 2009 [259]</td>
</tr>
<tr>
<td>SDF-1α</td>
<td>STZ diabetic mice</td>
<td>Increased EPC mobilization, homing and wound healing</td>
<td>Gallager et al, 2007 [260]</td>
</tr>
<tr>
<td>Stem cells</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bmscs</td>
<td>STZ diabetic rats</td>
<td>Promoted healing and improved the wound breaking strength. In addition, it increased collagen levels and TGF-β, KGF, EGF and VEGF expression</td>
<td>Kwon et al, 2008 [261]</td>
</tr>
<tr>
<td>CD133+ cells</td>
<td>STZ diabetic rats</td>
<td>Accelerated wound closure and promoted angiogenesis through stimulation of endothelial cell proliferation and migration</td>
<td>Barcelos et al, 2009 [262]</td>
</tr>
<tr>
<td>Human adipose-derived stromal cells</td>
<td>db/db diabetic mice</td>
<td>Increased wound closure and stimulated production of extracellular matrix proteins and secreted soluble factors</td>
<td>Amos et al, 2010 [263]</td>
</tr>
<tr>
<td>Embryonic stem cells</td>
<td>STZ diabetic rats</td>
<td>Reduced significantly wound size and increased expression of EGF and VEGF</td>
<td>Lee et al, 2011 [264]</td>
</tr>
<tr>
<td>EPCs</td>
<td>db/db diabetic mice</td>
<td>Promoted wound healing and vascularity and induced expression of VEGF and bFGF</td>
<td>Asai et al, 2012 [265]</td>
</tr>
<tr>
<td>Gene therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adenoviral PDGF-B</td>
<td>db/db diabetic mice</td>
<td>Significantly enhanced wound repair and neovascularization. In addition, adenoviral-PDGF-B stimulated EPC recruitment to the wound site</td>
<td>Keswani et al, 2004 [266]</td>
</tr>
<tr>
<td>Lentiviral-containing SDF-1α</td>
<td>STZ diabetic mice obese NOD/Ltj</td>
<td>Improved diabetic wound healing with completely epithelialization and increased the granulation tissue</td>
<td>Badillo et al, 2007 [267]</td>
</tr>
<tr>
<td>Adenoviral-Hox B3</td>
<td>db/db diabetic mice</td>
<td>Accelerated wound healing in diabetic mice</td>
<td>Mohedali et al, 2008 [268]</td>
</tr>
<tr>
<td>F-5 peptide (115-aa fragment of secreted Hsp90α)</td>
<td>db/db diabetic mice</td>
<td>Promoted diabetic wound closure through the recruitment of both epidermal and dermal cells and promoting dermal cell migration</td>
<td>Cheng et al, 2011 [269]</td>
</tr>
<tr>
<td>Proteins</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Substance P</td>
<td>db/db diabetic mice</td>
<td>Enhanced wound repair and increased early inflammatory density in the healing wounds</td>
<td>Gibran et al, 2002 [270]; Scott et al, 2008 [271]</td>
</tr>
<tr>
<td>Erythropoietin</td>
<td>STZ diabetic rats</td>
<td>Significantly reduced the time of total wound closure, increased micro vascular density, VEGF, and hydroxyproline contents and reduced extent of apoptosis</td>
<td>Hamed et al, 2010 [272]</td>
</tr>
<tr>
<td>Insulin</td>
<td>STZ diabetic rats</td>
<td>Enhanced wound healing and stimulated a faster epithelialization</td>
<td>Apikiglu-Rabus et al, 2010 [273]</td>
</tr>
<tr>
<td>Natural products</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lithospermun erythrorhizon extract</td>
<td>db/db diabetic mice</td>
<td>Decreased vascular permeability, formation of granulation tissue and accelerated wound healing</td>
<td>Fujita et al, 2003 [274]</td>
</tr>
<tr>
<td>Aqueous extract of Rosmarinus officinalis (Rosemary)</td>
<td>STZ diabetic rats</td>
<td>Promoted ulcer healing accelerating the processes of tissue regeneration, angiogenesis and inflammation</td>
<td>Lau et al, 2009[275]</td>
</tr>
<tr>
<td>Rehmanniae radix</td>
<td>Alloxan diabetic mice</td>
<td>Reduced inflammation and enhancement of wound contraction, re-epithelialization and regeneration of granulation tissue, angiogenesis and collagen deposition in the treated wounds</td>
<td>Abu-al-Basal et al, 2010 [276]</td>
</tr>
<tr>
<td>Ampucare (polyherbal ingredient)</td>
<td>Alloxan diabetic rats</td>
<td>Significantly reduced the wound size and bacterial count in wound site. Stimulated a well organized fibrous tissue proliferation, epithelialization and complete scar formation</td>
<td>Dwivedi and Chaudhary, 2012 [277]</td>
</tr>
<tr>
<td>Ethanolic extract of Annona squamosa</td>
<td>STZ diabetic rats</td>
<td>Enhanced rates of epithelialisation and wound contraction. Increased cellular proliferation and collagen synthesis at the wound site</td>
<td>Ponrasu et al, 2012 [278]</td>
</tr>
</tbody>
</table>
grade 0 (no ulcer in a foot with a high-risk factor of complication); grade 1 (partial/full thickness ulcer); grade 2 (deep ulcer, penetrating down to ligaments and muscle, but no bone involvement); grade 3 (deep ulcer with cellulitis or abscess formation); grade 4 (localized gangrene); and grade 5 (extensive whole foot gangrene) [64]. The classification of DFUs is important as it may facilitate the choice of suitable dressing depending on the wound type and on its phase [65].

This choice depends on several factors that will be discussed in the following sections.

3. Wound dressings for DFU treatment

3.1. Types and main characteristics of wound dressings

Natural skin is considered the perfect wound dressing and therefore an ideal wound dressing should try to replicate its properties [66]. Historically, wound dressings were first considered to play only a passive and protective role in the healing process. However, in recent decades wound treatment has been revolutionized by the discovery that moist dressings can help wounds heal faster [67,68]. Furthermore, a moist wound environment is also an important factor to induce the proliferation and migration of fibroblasts and keratinocytes as well as to enhance collagen synthesis, leading to reduced scar formation [69,70].

Besides assuring optimal moisture for wound environments, it is currently accepted that a wound dressing should also: (i) have the capacity to provide thermal insulation, gaseous exchange, and to help drainage and debris removal thus promoting tissue reconstruction processes; (ii) should be biocompatible and not provoke any allergic or immune response reaction; (iii) should protect the wound from secondary infections; and (iv) should be easily removable without causing trauma [66,71].

Due to the distinct characteristics of the different types of wounds and of each of the wound healing stages, there is no one single dressing that can be efficiently applied in all situations [72]. However, it is possible to develop and to optimize different biocompatible wound dressing materials in terms of their chemical and physical properties, e.g. moisture absorption and permeation capacities, in order to meet most of the needs for a particular wound stage [73].

In general terms and according to their main types and characteristics, the most commonly used wound dressings for diabetic wound healing applications can be easily classified as follows:

1. **Hydrocolloids**—these systems are moist wound dressings and usually comprise a backing material (e.g. semi-permeable films, foams or non-woven polyester fibers) and a layer with hydrophilic/colloidal particles that may contain biocompatible gels made of proteins (e.g. collagen, gelatin) or of polysaccharides (e.g. cellulose and its derivatives) [67,74,75]. When in contact with wound exudate, these dressings will absorb wound fluids, thus creating a moist environment [75,76]. They also have the capacity to be semi-permeable to water and oxygen [74]. However, the application of hydrocolloid dressings in strongly infected wounds has been questioned due to the possible hypoxic and excessively moist environment that could potentiate autolysis of necrotic tissue and therefore increase the risk of infection at the wound site [77,78]. Hydrocolloids are usually applied to granulating and epithelializing wounds and therefore they may be also used for necrotic wounds in order to promote wound debridement [76]. In average, these materials can be maintained on DFUs for more than
one week [74]. However, there are contradictory studies on whether hydrocolloid-type wound dressings can be used in diabetic foot wounds in the case of superficial wounds, if there are no signs of infection, or if few or moderate wound exudates are present [78].

(2) Hydrogels—these systems are mostly used to maintain highly moist wound environments and are comprised of single or mixed hydrated polymers (i.e. in the form of a gel) presenting at least 20% of their weight in retained water [73,79]. If the water content is higher than 95%, these materials are usually designated as superabsorbents [77]. Hydrogels may be covalently or non-covalently cross-linked in order to control their swelling capacities and to maintain their conformational structures [67], and they may swell (or shrink) reversibly in aqueous environments of specific pH and ionic strength values [80]. Like hydrocolloid dressings, hydrogels are capable of promoting the autolytic debridement of necrotic tissues and are usually more efficient at drying wounds with few exudates [79]. Their application in wounds having excess exudate can cause wound maceration and lead to healing problems [81]. A great advantage of hydrogel-type wound dressings is that they can usually be applied/removed without greatly interfering with the wound beds [73,74]. In addition, these dressings are flexible, non-antigenic, and permeable to water, oxygen and metabolites [67].

(3) Foams—foam-type dressings were developed as alternatives to hydrocolloid-type dressings for applications in moderate/high draining wounds [82]. Their capacity to absorb wound fluids is in general dependent on the specific polymeric material employed and on the foam thickness [73]. These dressings are highly absorbent, cushioning, protective and conformable to body surfaces [83]. Moreover, they are easy to manipulate and can be adapted to the required wound size [74,77]. Due to their absorbency and protective characteristics, foam-type dressings can be left on the wound for up to seven days [83]. Therefore, foams have been also proposed as potential candidates for DFU treatment [77,82].

(4) Films—these types of wound dressings are normally transparent, durable, conformable, easy to manipulate, adhesive, cheap, semi-permeable to oxygen and water vapor, and often impermeable to liquid and to bacterial contamination [73,83]. The main disadvantage of film-type dressings is that they should only be used for wounds with few exudates, namely as protective dressings in superficial pressure wounds and in applications that usually last 4–5 days before the dressing is replaced [73,74,77]. However, they may be used directly on the wound or in association with other types of dressings in order to better fix those in the wound bed or to improve their fluid barrier properties [69,73]. Film-type dressings have been also developed and employed in DFU treatment [74]. The main characteristics of each of these materials are summarized in Fig. 3.

Different synthetic and natural polymer-based biocompatible materials, as well as their mixtures or combinations and different processing methodologies, have been proposed and assayed both in vitro and in vivo for wound dressing (and DFU) applications [84–86]. Some of these materials are already commercially available and in clinical use [87,88]. To supplement and enhance the general wound dressing functions several different strategies have been developed, namely those involving the incorporation of bioactive compounds (e.g. growth factors, peptides, synthetic drugs and/or naturally based compounds/extracts) and of stem cells into dressing matrices in order to prepare medicated dressings [89–92].

3.2. Polymeric wound dressings for DFU treatment

Wound healing efficiency depends on several factors such as the wound type and stage, the extent of injury, patient condition, the tissues involved, as well as on the dressing selected, and on the effect of healing enhancers and therapeutic substances (if employed). Wounds can be treated using passive or hydroactive dressings [93]. The first are usually used for acute wounds (as they absorb reasonable amounts of exudates and they can ensure good protection), while the latter are normally used for chronic wounds (as they easily adapt to wounds and are able to maintain a moist environment that can stimulate the healing process) [83]. In both cases, and as already noted, drugs and/or other healing enhancers can be incorporated into the wound dressing polymeric matrices mostly to improve and accelerate healing.

Different constituent polymeric materials, exhibiting distinct chemical, physical and biological properties, may be employed in the preparation of wound dressing systems of different designs, dimensions and shapes, in order to obtain final products offering different final functional properties [72,94]. One of the simplest ways to differentiate those polymeric materials is by considering their origin: synthetic or naturally based polymers and copolymers [95]. Modified polymeric materials (those obtained by chemical

---

Fig. 3. Classification of the different dressing types usually used in DFU treatment.
<table>
<thead>
<tr>
<th>Polymers</th>
<th>Bioactive substance</th>
<th>Models used</th>
<th>Results</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chitosan and derivatives</td>
<td>Chitosan-crosslinked collagen aFG</td>
<td>Recombinant human STZ diabetic</td>
<td>Accelerated wound healing promoting a faster tissue collagen deposition, higher TGF-β1 expression and dermal cell proliferation.</td>
<td>Wang et al, 2008 [284]</td>
</tr>
<tr>
<td></td>
<td>Chitosan with different degrees of</td>
<td>Acetylglucosamine oligomers</td>
<td>Decreased wound size and stimulated angiogenesis and reepithelialization after seven days.</td>
<td>Ben-shalom et al, 2009 [285]</td>
</tr>
<tr>
<td></td>
<td>deacetylation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thiolated chitosan-oxidized dextran</td>
<td>STZ diabetic mice</td>
<td>Showed to be non-cytotoxic, resistant to degradation and capable of stimulating tissue regeneration.</td>
<td>Zhang et al, 2011 [286]</td>
</tr>
<tr>
<td></td>
<td>hydrogel</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chitosan, alginate, and poly(γ-glutamic</td>
<td>STZ diabetic rats</td>
<td>Enhanced wound healing. Stimulated collagen deposition, hydroxyproline levels and promoted skin epithelialization. Showed antibacterial properties.</td>
<td>Lee et al, 2012 [85]</td>
</tr>
<tr>
<td></td>
<td>acid) hydrogel</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hyaluronic acid and derivatives</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HA benzyl ester films</td>
<td>Autologous human keratinocytes</td>
<td>Induced healing of 79% of DFUs between 7 and 64 days.</td>
<td>Lohmann et al, 2003 [287]</td>
</tr>
<tr>
<td></td>
<td>Poly-N-acetyl glucosamine (pGlcNAc)</td>
<td>db/db diabetic mice</td>
<td>Wounds dressed reached 90% closure in 16.6 days. 9 days faster than untreated wounds. Higher levels of proliferation and vascularization were observed in granulation tissue.</td>
<td>Scherer et al, 2009 [288]</td>
</tr>
<tr>
<td></td>
<td>pGlcNAc membrane</td>
<td>db/db diabetic mice</td>
<td>Accelerated wound closure mainly by reepithelialization and increased keratinocyte migration, granulation tissue formation, cell proliferation, and vascularization. Up-regulated levels of VEGF, uPAR and MMP3, MMP9.</td>
<td>Pietramaggi et al, 2008 [290]</td>
</tr>
<tr>
<td></td>
<td>High molecular weight sodium hyaluronate</td>
<td>Iodine complex-Hyiodine</td>
<td>Reduced significantly the size of diabetic ulcers.</td>
<td>Sobotka et al, 2007 [289]</td>
</tr>
<tr>
<td></td>
<td>HA gel (Vulcamin)</td>
<td>Mixture of amino acids</td>
<td>After 3 month, the ulcer area and the number of infective complications were clearly decreased.</td>
<td>Abbruzzese et al, 2009 [292]</td>
</tr>
<tr>
<td></td>
<td>Cellulose and derivatives</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cellulose dressing</td>
<td>Human patients with DFUs</td>
<td>Decreased the activity of Escherichia coli and of Staphylococcus aureus bacteria by 99.99% in wounds.</td>
<td>Jung et al, 2009 [149]</td>
</tr>
<tr>
<td></td>
<td>Collagen/oxidized regenerated cellulose</td>
<td>Human patients with non-healing</td>
<td>Application in neuropathic DFUs during 6 weeks stimulated wound healing.</td>
<td>Lazaro-Martinez et al, 2010 [293]</td>
</tr>
<tr>
<td></td>
<td>foam</td>
<td>ulcers</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Microbial-derived cellulose hydrogel</td>
<td>Human patients with non-healing</td>
<td>Inhibit the proliferation of bacteria, provided an optimal moist healing environment through the absorption of excess fluid from exudating wounds. Remove necrosis and hyper granulation tissue to normal levels. Improvement in healing process was verified.</td>
<td>Serafica et al, 2010 [150]</td>
</tr>
<tr>
<td></td>
<td>Collagen/oxidized regenerated cellulose</td>
<td>Human patients with non-healing</td>
<td>Significant decrease the expression of proteases, such as elastase, plasmin, and gelatinase in wound exudates.</td>
<td>Ulrich et al, 2011 [294]</td>
</tr>
<tr>
<td></td>
<td>foam</td>
<td>DFUs</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Microbial cellulose</td>
<td>Human patients with non-infected</td>
<td>Treated wounds healed after 32 days which was faster than the 48 days necessary to heal control wounds.</td>
<td>Solway et al, 2011 [142]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DFUs</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carboxymethyl cellulose hydrogel</td>
<td>Chestnut honey db/db mice</td>
<td>Significant reduction of wound area, an increase of tissue granulation and an early-induction of HO-1 were verified at the wound site.</td>
<td>Choi et al, 2012 [295]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alginate</td>
<td>Phenytoin</td>
<td>Eradicated infection, reduced pain and led to 60% of wound closure after 16 weeks of treatment.</td>
<td>Shaw et al, 2011 [296]</td>
</tr>
<tr>
<td></td>
<td>Alginate gel</td>
<td>Honey</td>
<td>Satisfactory healing and stimulated tissue reepithelization.</td>
<td>Molan et al, 2011 [297]</td>
</tr>
</tbody>
</table>

(continued on next page)
<table>
<thead>
<tr>
<th>Polymers/Gelatin</th>
<th>Bioactive substance</th>
<th>Models used</th>
<th>Results</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collagen/Gelatin</td>
<td>Gelatin microspheres</td>
<td>bFGF</td>
<td>db/db mice</td>
<td>Reduced infection, accelerated fibroblast proliferation and capillary formation.</td>
</tr>
<tr>
<td>Collagen dressing</td>
<td>–</td>
<td>Human patients with DFUs</td>
<td>60% of them healed after two weeks of treatment. A decrease of infection by bacteria and an augment of granulation tissue were also observed.</td>
<td>Singh et al, 2011 [181]</td>
</tr>
<tr>
<td>Collagen matrix, Integra* (Integra LifeSciences Corp., USA)</td>
<td>–</td>
<td>Human patients with DFUs at high risk of amputation</td>
<td>Salvaged 46% of the limbs, increased the bacterial clearance and created a bed of granulation tissue.</td>
<td>Iorio et al, 2011 [298]</td>
</tr>
<tr>
<td>Collagen matrix</td>
<td>Glucose oxidase</td>
<td>STZ diabetic rats</td>
<td>Increased cellular proliferation and stimulated a faster wound contraction.</td>
<td>Arul et al, 2012 [182]</td>
</tr>
<tr>
<td>Collagen–gelatin foam</td>
<td>bFGF</td>
<td>db/db mice</td>
<td>Accelerated dermis tissue formation and increased the number of new capillaries.</td>
<td>Kanda et al, 2012 [186]</td>
</tr>
</tbody>
</table>

| Fibrin | Fibrin scaffold | AdeNOS | alloxan diabetic rabbit | Enhanced wound healing, eNOS expression, the inflammatory response and led to a faster rate of re-epithelialisation in an. | Breen et al, 2008 [98] |
| Combined single-donor platelet gel and fibrin glue | – | Human patients with DFUs | Stimulated wound closure. | Chen et al, 2010 [188] |
| Leucopatch* (naturally coagulated fibrin) | – | Human patients with DFUs | Wound area decreased significantly by 65%. | Jorgensen et al, 2011 [299] |
| Fibrin gel | CD34+cells | STZ-diabetic mice | Stem cells together with fibrin gel enhanced wound healing. | Pedroso et al, 2011 [189] |

| Dextran | Dextran-allyl isocyanate-ethylamine/polyethylene glycol diacrylate hydrogel | – | Human patients with chronic wounds | Promoted dermal regeneration, facilitated the early inflammatory cell infiltration and promoted cell migration into the wounds. | Sun et al, 2011 [197] |
| PVA | PVA aminated hydrogel | NO | db/db mice | Increased collagen production, enhanced the quality of the granulation tissue and increased the wound strength. | Bohl et al, 2002 [215] |
| | Aminophenyl boronic acid with PVA | Ciprofloxacin | Diabetic human patients | Promoted an efficient release of anti-bacterial drugs to improve complications in long term healing wounds. | Manju et al, 2010 [216] |
| PEG | PCL-PEG block copolymer | rhEGF | STZ diabetic mice | Induced faster wound healing with high proliferation and keratinocytic expression at the wound site. | Choi et al, 2008 [229] |
| | PEG-PCL nanofibers | EGF and bFGF | STZ diabetic mice | Increased the accumulation of collagen and keratin and reduced scar formation. | Choi et al, 2011 [230] |
| | PEGylated fibers | rhaFGF | STZ diabetic rats | Stimulated wound closure, tissue collagen formation and earlier and higher TGF-β expression. | Huang et al, 2011 [227] |
| | Poly(ethylene imine) and PEG | plasmid bFGF | STZ diabetic rats | Significantly increased the wound recovery rate, enhanced collagen deposition and maturation and complete re-epithelialization. | Yang et al, 2012 [226] |
| PVP | Poly (vinyl methyl ether co-maleic anhydride) and PVP | NO | STZ diabetic rats | The complex controlled release of NO and accelerated wound closure. | Li and Lee, 2010 [234] |
PU-based foam 

Maintain a moist wound environment and to absorb the excessive wound exudates and dead tissues. 

Varma et al, 2008 [238] 

PHEMA and by PEG hydrogel 

Promoted a faster healing rate as well as fibroblast proliferation, 

Rayment et al, 2010 [247] 

Poly (a-esters) PLGA microspheres rhEGF 

Enhanced the growth rate of fibroblasts and the wound healed more efficiently. 

Dong et al, 2008 [252] 

PCL nanofibers Curcumin 

These nanofibres increased the rate of wound closure. 

Merati et al, 2010 [255] 

PLA fibers bFGF 

Higher wound recovery rate with complete re-epithelialization, regeneration of skin appendages, higher density and mature capillary vessels. 

L.I.F. Moura et al. / Acta Biomaterialia 9 (2013) 7093–7114 [99] 

3.2.1. DFU dressings based on natural polymers 

Chitin, chitosan and derivatives. Chitin is one of the most abundant polysaccharides in nature. It can be found in the exoskeleton of arthropods, of crustacea, of some mollusks and in the cell walls of fungi [105]. Common chitin sources (e.g. shells of shrimps and crabs) are very accessible at low cost, making chitin a commercially attractive biomaterial for various applications [106,107]. Chitin is a linear polysaccharide of N-acetyl-D-glucosamine (2-acetamido-2-deoxy-D-glucose) units linked by β-(1-4) glycosidic bonds [84,108–111]. As chitin is not soluble in aqueous solutions, it is usually converted into chitosan by thermochemical deacetylation in the presence of an alkaline solution [111,112]. Therefore, chitosan is a linear copolymer of D-glucosamine and of N-acetyl-D-glucosamine. The term chitosan is also usually employed to describe a series of chitin derivatives having different degrees of deacetylation (defined in terms of the composition of primary amino groups in the polymer backbone and of their average molecular weights) [112].

The chemical, physical and biological properties of chitosan are directly related to its deacetylation degree and to its molecular weight [113], and chitosan is generally regarded to be biodegradable, biocompatible, non-antigenic, non-toxic, bioadhesive, anti-microbial, bioactive and to have hemostatic effects [103,105,114]. It is also easily degraded by chemical hydrolysis as well as by certain human enzymes, namely lysozyme [109,110]. In addition, chitosan amino and hydroxy groups can be easily reacted and chemically modified, thus allowing a high chemical versatility. For example, chitosan may be modified into N-carboxymethyl chitosan [115], N-carboxybutil chitosan [116,117], N-succinyl chitosan [118], N-acyl chitosan [119], N,N-(carboxymethyl) chitosan [120], N,N-dicarboxymethyl chitosan

Modification of naturally based polymers [96] or mixtures/combinations of different polymers and copolymers [97] can also be considered.

For DFU applications, a wide variety of polymeric materials has already proved to enhance healing and some of these are now commercially available [98,99]. Some of the commonly used polymer-based materials used to produce dressings for DFU treatment will be presented hereafter and a brief description of their structure–property relationships are provided in Table 2. Some examples of commercial dressings currently available for this purpose are also described in Table 3.
Table 3
Commercial dressings used for DFU treatment.

<table>
<thead>
<tr>
<th>Commercial dressing</th>
<th>Fabricant</th>
<th>Composition</th>
<th>Main characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bionect®</td>
<td>Dara BioScience</td>
<td>0.2% of sodium salt of hyaluronic acid</td>
<td>Easy to use, reduces the incidence of high-grade skin reactions, reduces wound severity</td>
</tr>
<tr>
<td>Unite® Biomatrix</td>
<td>Synovis Orthopedic and WoundCare, Inc.</td>
<td>Non-reconstituted collagen</td>
<td>Collagen dressing helps maintain wound bed in healing phase, allows for healthy granulation tissue and wound closure, absorbs excess exudate allowing few dressing changes, easily conforms to the wound bed, strong and durable</td>
</tr>
<tr>
<td>BGC Matrix®</td>
<td>Mölnlycke Health Care US, LLC</td>
<td>Collagen and the advanced carbohydrate beta-glucan</td>
<td>Protects underlying tissue from external contamination, provides structural support for new cell growth, adherent, flexible and conformable, minimizes protein and water loss, collagen aids in hemostasis, minimizes pain</td>
</tr>
<tr>
<td>Promogran Prisma® Matrix</td>
<td>Systagenix</td>
<td>Collagen, ORC and silver-ORC matrix</td>
<td>In the presence of exudate, the matrix transforms into a biodegradable gel, maintains a moist wound environment, and creates ideal conditions for healing, antimicrobial silver chloride prevents colonization of the dressing, easy to use</td>
</tr>
<tr>
<td>Dermacol/Ag™ Collagen Matrix</td>
<td>DermaRite Industries</td>
<td>Collagen, sodium alginate, carboxyl methyl- cellulose, ethylenediamine- tetraacetic acid (EDTA) and silver chloride</td>
<td>Transforms into a soft gel sheet when in contact with wound exudates, maintains a moist wound environment, and creates ideal conditions for healing, antimicrobial silver chloride prevents colonization of the dressing, easy to use</td>
</tr>
<tr>
<td>Fibracol® Plus Collagen Wound</td>
<td>Systagenix</td>
<td>Collagen and calcium alginate fibers wound</td>
<td>Structural support of collagen with gel forming properties of alginates, maintains a moist wound environment, and creates ideal conditions for healing, adherent, flexible and conformable, sterile and soft</td>
</tr>
<tr>
<td>Aqualc Hydrofiber® Wound Dressing</td>
<td>ConvaTec</td>
<td>Antimicrobial hydrofiber containing carboxymethyl cellulose with ionic silver</td>
<td>Absorbs wound fluid and creates a soft gel, which maintains a moist wound environment, absorbs and retains exudate and harmful components, such as bacteria contained within exudate, directly into its fibers, helps reduce the pain and trauma upon dressing removal, conforms to the wound surface, used on moderately and highly exuding chronic wounds</td>
</tr>
<tr>
<td>Regranex® Gel</td>
<td>Healthpoint Biotherapeutics</td>
<td>rh PDGF-BB incorporated in aqueous sodium carboxymethylcellulose</td>
<td>Stimulates wound healing processes and aids in creation of granulation tissue, only FDA-approved topical agent with platelet-derived growth factor, promotes the recruitment and proliferation of chemotactic cells, stimulates wound closure, easy to use</td>
</tr>
<tr>
<td>MediHoney® Adhesive Honeycolloid</td>
<td>Derma Sciences, Inc.</td>
<td>80% active Leptospermum honey with colloidal alginate</td>
<td>Maintains effectiveness even in the presence of wound fluid, blood and tissue, for wounds with light to moderate amounts of exudates, pad will form a gel as it warms up and contacts wound fluid, promotes a moisture-balanced environment conducive to wound healing, helps wounds that have stalled progress toward healing, high osmolarity cleanses, helps lower overall wound pH, non-toxic, natural, safe and low-cost</td>
</tr>
<tr>
<td>MediHoney® Calcium Alginate Dressing</td>
<td>Derma Sciences, Inc.</td>
<td>Contains 95% active Leptospermum honey with calcium alginate</td>
<td>As wound fluid enters the dressing, the honey is released while the dressing forms a gel, maintains effectiveness even in the presence of wound fluid, blood and tissue, promotes a moisture-balanced environment conducive to wound healing, highly osmotic and helps to reduce overall wound pH, for wounds with moderate to heavy amounts of exudates, non-toxic, natural, safe and easy to use</td>
</tr>
<tr>
<td>Commercial dressing</td>
<td>Fabricant</td>
<td>Composition</td>
<td>Main characteristics</td>
</tr>
<tr>
<td>---------------------</td>
<td>-----------</td>
<td>-------------</td>
<td>----------------------</td>
</tr>
<tr>
<td><strong>Algisite</strong>&lt;br&gt;Calcium Alginate Dressing</td>
<td>Smith &amp; Nephew, Inc.</td>
<td>Calcium-alginate</td>
<td>- Forms a gel that absorbs exudate when in contact with wound&lt;br&gt;- Helps prevent scar formation and promotes wound contraction&lt;br&gt;- Allows gas exchange necessary for a healthy wound bed&lt;br&gt;- Low-adherence reduces trauma at dressing changes&lt;br&gt;- Conforms to wound contours&lt;br&gt;- Low fiber shed&lt;br&gt;- Easy to remove</td>
</tr>
<tr>
<td><strong>Sorbalg®</strong></td>
<td>Hartman USA, Inc.</td>
<td>Calcium alginate</td>
<td>- Forms a hydrophilic gel on contact with wound exudate&lt;br&gt;- Maintains integrity while dry or wet&lt;br&gt;- High absorbent&lt;br&gt;- Easy to remove&lt;br&gt;- Latex-free</td>
</tr>
<tr>
<td><strong>Kaltostat®</strong> Dressing</td>
<td>ConvaTec</td>
<td>Sodium and calcium salts of alginic acid</td>
<td>- In the presence of exudate or other body fluids containing sodium ions, the fibers absorb liquid and swell&lt;br&gt;- Calcium ions present promote the dressing to take on a gel-like appearance&lt;br&gt;- Facilitates wound healing providing a favourable micro-environment&lt;br&gt;- Easy to use</td>
</tr>
<tr>
<td><strong>Tegaderm™ High Gelling Alginate Dressing</strong></td>
<td>3 M Health Care</td>
<td>Polyurethane dressing containing alginate</td>
<td>- Forms a gel-like consistency as it absorbs exudate to provide a moist healing environment&lt;br&gt;- Completely gels with saturation for easy removal from fragile tissue by gentle irrigation&lt;br&gt;- Easily irrigated from the wound bed when saturated&lt;br&gt;- Highly absorbent dressings and conformable</td>
</tr>
<tr>
<td><strong>GranuDerm™ Sentry™</strong></td>
<td>Acute Care Solutions, LLC</td>
<td>Alginate hydrocolloid with polyurethane</td>
<td>- Breathable film membrane surrounds the wound site&lt;br&gt;- Promotes wound repair&lt;br&gt;- Visually signals dressing changes&lt;br&gt;- Water, dirt and germ proof&lt;br&gt;- Reduces dressing changes&lt;br&gt;- Extended wear time&lt;br&gt;- Prohibits leakage</td>
</tr>
<tr>
<td><strong>Biatain® Heel Foam Dressing</strong></td>
<td>Coloplast Corp.</td>
<td>3-D non-adhesive foam of polyurethane</td>
<td>- Foam absorbs and retains wound exudate to control moisture balance in wound&lt;br&gt;- Absorbs low-to-high wound exudate levels and protects the heel&lt;br&gt;- Decrease wound area and prevents skin maceration&lt;br&gt;- Soft, beveled edges makes dressing more comfortable for patient&lt;br&gt;- Longer wear time for fewer dressing changes&lt;br&gt;- Low risk of leakage or maceration&lt;br&gt;- Safe and effective</td>
</tr>
<tr>
<td><strong>Biatain Ibu Foam Dressing Non-adhesive</strong></td>
<td>Coloplast Corp.</td>
<td>Combination of polyurethane-foam, polyurethane film, polyethylene and ibuprofen</td>
<td>- Combines moist wound healing with an active pain reliever&lt;br&gt;- Releases ibuprofen evenly into the wound&lt;br&gt;- Helps to ease pain from the wound during wear and when changing the dressing&lt;br&gt;- Promotes wound repair&lt;br&gt;- Easy to use</td>
</tr>
<tr>
<td><strong>MANUKAh®</strong></td>
<td>ManukaMed USA, Inc.</td>
<td>Polyurethane foam and film in backing and an absorbent dressing pad of polyacrylate polymers impregnated with ManukaMed® honey</td>
<td>- 100% active medical grade Manuka® honey&lt;br&gt;- Gentle on wounds promoting wound healing&lt;br&gt;- Forms gels in contact with exudate&lt;br&gt;- Fluid permeable and dry-touch</td>
</tr>
<tr>
<td><strong>DuoDERM® CGF®</strong></td>
<td>ConvaTec</td>
<td>Polyurethane foam</td>
<td>- Promotes granulation and facilitates autolytic debridement&lt;br&gt;- Can be easily and gently molded into place&lt;br&gt;- Use on lightly to moderately exuding acute and chronic wounds&lt;br&gt;- Minimize skin trauma and disruption of healing&lt;br&gt;- Can be worn for up to 7 days&lt;br&gt;- Allows observation of the healing process due to its transparency</td>
</tr>
<tr>
<td><strong>SOLOSITE® Conformable Wound Gel Dressing</strong></td>
<td>Smith &amp; Nephew, Inc.</td>
<td>Polyurethane and polyethylene hydrogel</td>
<td>- Creates a moist wound healing environment&lt;br&gt;- Keeps gel in intimate contact with wound surface&lt;br&gt;- Absorbs excess exudate allowing few dressing changes&lt;br&gt;- Non-cytotoxic and non-sensitizing</td>
</tr>
<tr>
<td><strong>Silverlon® Island Wound Dressing</strong></td>
<td>Argentum Medical, LLC</td>
<td>Polyurethane film containing silver</td>
<td>- Non-adherent wound contact layer&lt;br&gt;- Provides effective protection against microbial contamination&lt;br&gt;- Permits passage of wound exudate&lt;br&gt;- Stimulates wound repair&lt;br&gt;- Easy to apply</td>
</tr>
</tbody>
</table>

(continued on next page)
Hyaluronic acid and other glycosaminoglycans. Hyaluronic acid (HA) is a natural polysaccharide, namely a non-sulfated glycosaminoglycan (GAG), which is a major component of the ECM of the connective tissues of certain mammals such as cartilage, eye vitreous humor, umbilical cord and synovial fluid [67,101]. HA is also referred to as hyaluronan due to the fact that it usually exists in vivo as a polyanion and not in the protonated acidic form [133]. It is a linear polysaccharide of alternating disaccharide units of α-1,4-glucuronic acid and β-1,3-N-acetyl-D-glucosamine, linked by β(1→3) glycosidic bonds [126]. HA is usually extracted from the umbilical cord, vitreous humor, synovial fluid or from rooster combs [134]. When extracted from the host body, HA is non-allergenic and biocompatible [135,136]. However, it is already easily produced on a large scale and in a controllable and reproducible way by microbial fermentation [133]. HA is water soluble up to certain concentrations and can produce highly viscous solutions with unique viscoelastic properties. It can form three-dimensional structures in ex vivo aqueous solutions through hydrogen bonding [133].

HA presents many important physiological functions such as structural and space-filling properties, lubrication, as well as tissue and ECM water sorption and retention abilities [135,137]. HA is also an interesting biomaterial for wound healing applications since it is known to promote mesenchymal and epithelial cell migration and differentiation, thus enhancing collagen deposition and angiogenesis [133,136,138].

HA’s chemical and physical properties, namely its mechanical properties and degradation profiles, are strongly dependent on its molecular weight. Native high molecular weight HA has important structural properties, whereas its degradation products may stimulate endothelial cell proliferation and migration, modulate the inflammatory processes and promote angiogenesis during the different wound healing stages [137,139,140]. A large number of studies involving the use of HA in the context of DFU, processed as foams or gels, with or without bioactive substances, have been reported and these are summarized in Table 2.

### 3.2.1.2. Hyaluronic acid and other glycosaminoglycans.

#### 3.2.1.3. Cellulose and its derivatives.

Cellulose is the primary structural component of plant cell walls and is the most abundant organic polymer on Earth. Therefore, it is a renewable biomaterial, readily available at low cost [101]. Furthermore, it can also be eas-

### Table 3 (continued)

<table>
<thead>
<tr>
<th>Commercial dressing</th>
<th>Fabricant</th>
<th>Composition</th>
<th>Main characteristics</th>
</tr>
</thead>
</table>
| Allevyn             | Smith & Nephew, Inc. | Polyurethane films combined with polyurethane foam containing 5% silver sulphadiazine. | • Minimizes pain to the patient and trauma to the wound at dressing change  
• Rapid and sustained (7 days) antibacterial action  
• Absorbs, retains and transpires exudate to provide enhanced fluid management  
• Provides a moist wound environment for the promotion of faster closure  
• Stays in place for up to 7 days |
| Melplex Ag          | Molnlycke Health Care | Polyurethane foam containing a silver compound (silver sulphate) | • Vapor-permeable  
• Waterproof film to absorb exudate  
• Maintains a moist wound environment |
| Ligasano            | Ligasano | Honeycomb-polyurethane foam | • Economic and manageable  
• Absorbs high amounts of exudate without dehydrating the wound bed  
• Creates a moist and warm wound environment  
• Antiseptic and cleans the wound with no sticking to the wound  
• Stimulates local blood circulation in the wound |
ily converted into several potentially advantageous derivatives. Cellulose is a linear polymer constituted by β-1,4 linked d-glucose units which are joined to form cellulose repeating units [141]. Cellulose glucan chains are parallel and are packed side-by-side, forming microfibrils, stabilizing the structure but minimizing its flexibility. The degrees of polymerization and the molecular organization of its chains are the main characteristics that affect the chemical and physical properties of cellulose and thus its processing methods and applicability [142]. This highly cohesive hydrogen-bonded structure provides cellulose fibers of great stability, rigidity and tensile strength and makes them water insoluble (despite their hydrophilic character). Cellulose and its derivatives are slightly degradable by several bacteria and fungi present in air, water and soil, which leads to a decrease in its mechanical strength and to an improvement in its water solubility [141,143]. In addition, cellulose-based materials are considered biocompatible due to their reduced inflammatory response to foreign bodies [143,144]. Moreover, resorption of cellulose in tissues does not occur since cells are not able to synthesize cellulases [144].

Some cellulose ether derivatives such as methyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl methyl cellulose and carboxymethyl cellulose are cold and/or hot water-soluble up to some concentrations and present other interesting properties such as organic-solvent solubility, thermoplastic behavior and biosurface activity. Cellulose ester derivatives, such as cellulose acetate, cellulose triacetate and cellulose sulfate, are also fiber- and film-forming materials [145]. Moreover, their molecular weights can be varied, and therefore their aqueous viscosities and gelation properties can be tuned [143,146]. These features allow their use in several pharmaceutical formulations and for various biomedical purposes.

Microbial (or bacterial) cellulose (MC) is different from plant-origin cellulose. It is synthesized by various bacteria and has already proved to present great potential for wound healing applications [147,148]. Its high mechanical strength, crystallinity and high capacity to retain water mostly arise from its unique nanofibrillar structure [143,147].

Some studies have demonstrated that cellulose stimulates wound healing through the release and maintenance of therapeutic levels of a number of growth factors (i.e., PDGF, epidermal growth factor (EGF) and FGF) at the wound site and by promoting dermal fibroblast migration and proliferation and inhibiting bacterial proliferation in wounds [149–151]. In this last case a significant improvement was observed by loading the dressing material with growth factors such as stromal derived factor-1 (SDF-1) or drugs such as phenytoin, ibuprofen or clindamycin to improve DFU treatment. Commercial products such as Medihoney (Derma Sciences Inc., Canada) which is an alginate hydrocolloid wound dressing loaded with a minimum of 70% of active Leptosperrum honey or Algisite M Calcium Alginate Dressing (Smith and Nephew Inc., Australia) are alginate-based dressings indicated for DFU treatment. These and other examples of the application of alginate dressings for DFU wound healing are summarized in Table 2.

3.2.1.5. Collagen and gelatin. Collagen is the most abundant protein of the ECMs naturally present in human tissues (e.g., skin, bone, cartilage, tendon and ligaments). It represents 25% of the total protein body content [80,102,160,161], providing strength and integrity to tissue matrices [162]. In addition, collagen can also interact with cells and help essential cell signaling that will regulate cell anchorage, migration, proliferation, differentiation and survival [101,120,162].

Twenty-seven types of collagens have already been identified, with types I–IV being the most common. Type I collagen is the most abundant protein present in mammals and is the most studied protein for biomedical applications [101,141].

Collagen degrades enzymatically within the body, mostly via collagenases, gelatinases and metalloproteinases [163]. In general terms, collagens are rod-type proteins with typical molecular weights around 300000 g mol⁻¹ that also present high mechanical strength and good biocompatibility (although they may present some antigenicity) [101,164]. Collagen can form stable fibers and its mechanical, degradation and water-uptake properties can be further enhanced by chemical cross-linking (using glutaraldehyde [165], genipin [166], carboimide [167], hexamethylene diisocynate [168]), by physical cross-linking (using freeze-drying) [169] or by binding with other protein/polymers [170,171]. Low inflammatory and cytotoxic responses and biodegradability are other attractive properties of collagen [102].

As a result, and since collagen is one of the major components of human ECMs, it is usually considered as an ideal biomaterial for tissue engineering and for wound dressing applications. Collagen is usually isolated from animal tissues, a source that raises some concerns [163,164]. However, enzymatic purification techniques

**3.2.1.4. Alginate.** Alginate (or alginic acid) is one of the most studied and applied polysaccharides in tissue engineering and drug delivery applications. It is abundant in nature since it is a structural component of marine brown algae (*Laminaria hyperborean*, *Ascophyllum nodosum* and *Macrocystis pyrifera*) and as capsular polysaccharides in some soil bacteria [101]. It is constituted by β-1,4-mannuronate (M-residues) and α-1,4-guluronate (G-residues) residues covalently linked in different alternating or random sequences/blocks [101,141,152]. Alginites can form reversible hydrogels through the interaction with divalent cations, such as Ca²⁺, Mg²⁺, Ba²⁺ or Mn²⁺, that can cross-link G-residues of adjacent alginate chains by means of ionic interactions [152]. Despite other applications, these easy cross-linking and processing strategies allow their wide use as three-dimensional supports for cell transplantation, as well as wound dressing biomaterials. Moreover, alginate has high biocompatibility, low toxicity and good mucoadhesive properties [101,141,153]. Alginate-based biomaterials are also pH sensitive and the release of bioactive species from these materials at low pH conditions is significantly reduced. Therefore, this feature could be advantageous for the development of a delivery system intended for near-neutral pH conditions [152].

However, alginate-based hydrogels may present unpredictable and uncontrollable degradation and dissolution profiles after loss of the divalent cation cross-linkers [153]. To overcome this issue, covalent/ionic cross-linking can be employed with other biopolymers such as gelatin [154], heparin [155], polyvinyl alcohol [156] and chitosan [157]. The other main disadvantage of alginate-based materials is their inability to undergo efficient and rapid enzymatic degradation in mammals. In addition, alginites are very hydrophilic, which hinders its interactions with skin proteins [152].

Calcium alginate-based dressings are recognized to have the capacity to efficiently absorb wound exudates, hence facilitating debridement and accelerating wound healing in DFU [82,158,159]. Alginate-based dressings have also been combined with growth factors such as stromal derived factor-1 (SDF-1) or drugs such as phenytoin, ibuprofen or clindamycin to improve DFU treatment. Commercial products such as Medihoney (Derma Sciences Inc., Canada) which is an alginate hydrocolloid wound dressing loaded with a minimum of 70% of active Leptosperrum honey or Algisite M Calcium Alginate Dressing (Smith and Nephew Inc., Australia) are alginate-based dressings indicated for DFU treatment. These and other examples of the application of alginate dressings for DFU wound healing are summarized in Table 2.
(to eliminate those immunogenic telopeptides that induce foreign body response) may be employed [172]. Alternatively, the use of recombinant and non-recombinant human collagens can be envisaged but their production currently incurs high costs [164]. Collagen is also difficult to process and its degradation rate cannot easily be controlled [101,163]. For example, collagen degradability depends on cell three-dimensional structure penetration (which causes contraction, inner pressure increase, fluid restrictions and makes collagen less swellable and degradable), and, in addition, collagen is also degradable by other non-specific proteinases [101]. Finally, collagen sterilization may be also an issue as the sterilization methods currently employed may promote chemical and physical modifications of the collagen structure [163].

Gelatin is a collagen derivative which is commonly used as an hydrogel for pharmaceutical and biomedical applications mostly because of its straightforward processability and good biodegradability/biocompatibility in physiological environments [101,173]. Moreover, gelatin has relatively low antigenicity because it is a denatured protein material (in contrast to collagen, which is known to present some antigenicity due to its unaltered animal origin) [102].

Gelatin can be obtained by the acidic or alkaline processing (denaturation) of collagen [174]. Consequently, two different types of gelatin can be obtained according to the methods employed for collagen pretreatment. These different pH pretreatments will also affect the isoelectric points of the gelatin biomaterials obtained, and manufacturers can now provide gelatin with a wide range of isoelectric point values, from alkaline gelatin (with an isoelectric point of 9.0) down to acidic gelatin (with an isoelectric point of 5.0) [101]. This is an important feature as it allows the complexation of gelatin with either positively or negatively charged biomolecules. Basic gelatin is preferable as the carrier matrix for an acidic bioactive molecule, while acidic gelatin should be employed for the release of basic bioactive substances [175].

In general terms, the release of these substances is controlled by the enzymatic degradation of the gelatin-based materials involved. Therefore, and similar to collagen, the degradation profiles (and the mechanical properties) of gelatin-based hydrogels may be adjusted by controlling the degree of cross-linking (which will also control the hydrogel water content) [176]. As for collagen cross-linking, it can be performed by chemical methods (e.g. using water-soluble carbodiimides [177], glutaraldehyde [178] or genipin [179]) or through physical cross-linking (by thermal treatment, by the formation of polynucle complexes with other polymers or by blending with other gelating polymers) [154,180].

Due to all the above-mentioned characteristics, collagen is frequently used to prepare wound dressing materials in diverse forms that include gels, pads, particles, pastes, powders, sheets or solutions. A large number of commercial collagen-based dressings is already available and some are specifically indicated for partial- and full-thickness pressure, venous, vascular and diabetic ulcers as is the case of BCG®, BIOSTEP®, Catrix®, CollaSorb® and PROMOGRAN PRISMA® Matrix (Table 3).

As reported in Table 2, recent studies have proved the efficacy of collagen and gelatin dressings for decreasing infection by bacteria and favoring granular tissue formation, stimulating faster wound healing in DFU patients [181–184]. Different approaches tested so far include the incorporation of glucose oxidase in a collagen matrix in order to achieve the sustained delivery of reactive oxygen species (ROS), natural compounds (such as polyphenols), growth factors (such as bFGF), antibiotics (such as doxycycline and levofloxacin) and ionic silver as antimicrobial agent [182,185,186].

3.2.1.6. Fibrin. Fibrin is a protein that is produced from fibrinogen and hence can be autologously harvested from patients. Therefore, it may provide immunocompatible polymeric carriers for the delivery of bioactive molecules and/or cells in various biomedical applications [101,102]. Polymerized fibrin is a major component of blood clots and is recognized to play an important role in the subsequent wound healing response [102,187]. On the other hand, fibrin contains some specific domains that may improve cell binding and, therefore it has also been studied as an advantageous biomaterial for cell adhesion, spreading, migration, proliferation and tube formation [101,153,187]. Due to these characteristics, fibrin-based biomaterials (including modified/cross-linked fibrin and fibrin composites) may also be applied for drug and cell delivery for tissue engineering applications. The most widely used forms of fibrin scaffolds are fibrin hydrogels and fibrin glue. Fibrin hydrogels are known to promote angiogenesis and to enhance neovascularization. A major drawback is that fibrin hydrogels have low mechanical stiffness, and rapid degradation may occur before the proper formation of tissue-engineered structures [187]. Finally, fibrin gels are biological adhesives commonly used in surgical procedures (mostly due to their hemostatic, chemotactic and mitogenic properties) [101]. These glues have also been described to facilitate the fixation of skin grafts and to limit the risk of infection in chronic wounds [188]. Fibrin gels can be obtained by the enzymatic cross-linking of fibrinogen with thrombin. The final structure of fibrin gels will thus depend on the concentration of thrombin and fibrinogen, on local pH and ionic strength, as well as on the local calcium concentration [189]. Wound healing improvements were obtained after application of fibrin gels incorporating hematopoietic stem cells (CD34+), CD34+-derived endothelial cells, or both. Since pluripotent stem cells are able to differentiate into fibroblasts, keratinocytes and endothelial cells, they may also play an important role during the wound healing process [189]. Bone marrow-derived stem cell transplantation can also be used for the healing of chronic lower extremity wounds. Hassan et al. [190] topically applied a concentrated solution of bone marrow stem cells combined with platelets and fibrin glue in a collagen dressing. After 4 weeks of treatment, diabetic ulcers were totally closed in three patients and significantly reduced in another five patients. Other approaches to enhance the effect of fibrin gels to improve healing include the use of enzymes to produce and deliver nitric oxide (NO) which enhances the inflammatory response and faster re-epithelialization, and the use of platelets that work as powerful mitogenic and chemostatic factors. The healing effect of Vivostat, a platelet-rich fibrin treatment for DFUs, has been studied in a clinical trial [191]. The ulcers of patients were treated from weeks 1 to 6 with Vivostat platelet-rich fibrin. The results showed that ulcers were completely healed after 12 weeks. These achievements are summarized in Table 2.

3.2.1.7. Silk fibroin. Fibrin protein can be isolated from the silk-worm (Bombyx mori or Antheraea mylitta). It is receiving attention for biomedical applications due to its biocompatibility, hemocompatibility, slow degradability, water vapor and gas permeability besides its widespread versatility [192,193]. Silk fibers are composed of a fibrous protein (fibrin) core and a glue protein (sericin) surrounding it. Even though fibroin does not promote immunological responses, silk sercin protein may have the opposite effect [194]. In addition, silk fibroin is able to support epidermal cells and fibroblast attachment, spreading and proliferation, thus promoting wound healing [101]. Fibrin films loaded with aloe gel extract were recently applied in the treatment of streptozotocin-induced diabetic rats [193]. Compared to aloe-free fibrin film, the blended film enhanced the attachment and the proliferation of skin fibroblasts. Moreover the wounds in diabetic rats presented a smaller area 7 days after wounding (when compared to untreated diabetic wounds) and fibroblast distribution and collagen fiber organization similar to wounds in normal rats. These results show that acceler-
ated wound healing can be obtained by using blended fibroin/loe gel films which may be applied in the treatment of diabetic non-healing skin ulcers.

3.2.1.8. Dextran. Dextran is constituted by α(1→6)-linked D-glucose residues with some degree of branching via α(1→3) linkages, and is obtained from various bacterial strains via the action of dextranase [101,141]. Dextran is hydrophilic, highly soluble in water, inert in biological systems and easily functionalized through its reactive hydroxyl groups [195,196]. Dextran is available in a wide range of molecular weights, as well as in the form of several dextran derivatives. It is biodegradable, biocompatible, resists protein adsorption and does not affect cell viability. Therefore it is a good polymer for medical applications such as bone, dermal and subcutaneous healing and for drug delivery [101,196]. It facilitates inflammatory cell infiltration and promotes angiogenic cell migration into the wounds [197]. Diabetic patients have been treated with dextranomer, a dextran polymer which is applied locally to the ulcer or the infected wound [198]. Wounds were covered with a thick layer of dextranomer and further covered with a dry absorbent gauze and non-occlusive bandage dressing. Of the 15 lesions treated, 12 healed completely (for an average period of 8 days) showing the potential of dextran-based materials to treat DFUs. This study showed that the effect of dextranomer on the infected wound was rapid, leading to a remarkable decrease of the inflammatory reaction around the wound during the first day and the formation of healthy granulation tissue within a few days without pain, edema and tenderness. According to this and other previous studies it was proposed that the enhanced effect of dextranomer is due to its capacity to cleanse the lesion by absorbing the wound exudate, protein degradation products, prostaglandins, bacteria and other contaminants, reducing inflammation and improving healing.

3.2.1.9. Elastin. Elastin is an insoluble ECM protein and a major constituent of skin elastic fibers [199,200]. Elastin is highly insoluble and difficult to process into new biomaterials. Nevertheless, its soluble forms, including tropoelastin (a soluble precursor form of elastin), α-elastin (an oxalic acid derivative of elastin) and elastin-like polypeptides have much broader applications as elastin-based biomaterials [200,201]. Elastin can also be cross-linked by chemical (e.g. using aldehydes and epoxide groups) [202,203], enzymatic [204] and physical processes [205]. These strategies allow an efficient binding to amino acids side chains, low antigenicity and improved mechanical strength [201]. Soluble elastin-based biomaterials promote a natural elasticity, favorable cellular interactions and enhanced tissue regeneration through increased chemotactic activity, fibroblast proliferation and collagenase synthesis [206]. Despite the scarcity of reports concerning the application of elastin-based dressings to DFU treatments, a recent study demonstrated that a protein gel comprised of elastin-like peptides was loaded with keratinocyte growth factor (KGF) enhanced the re-epithelialization and granulation of wounds in diabetic mice [199], indicating that elastin can be considered an interesting naturally derived and physical properties [173]. The risks of biological contamination are non-existent. In addition, some of these synthetic polymers are mainly degraded via chemical hydrolysis and are quite insensitive to a number enzymatic processes, and hence their degradation behavior will not vary greatly from patient to patient [173]. Synthetic polymers that are being used for the development of wound dressings, in particular those that can be used for DFU treatment, will be presented and discussed in the following section.

3.2.2.1. Poly(vinyl alcohol) (PVA). PVA is a hydrophilic, non-toxic, non-carcinogenic, biocompatible polymer obtained from vinyl acetate by alcoholysis, hydrolysis or aminolysis [61,80,153]. PVA has been widely used for tissue engineering and drug delivery applications, and besides its high hydrophilicity and water absorption capacity, it also presents an excellent capacity to be processed in the form of particles, fibers, textiles, sponges and films. Furthermore, it presents good chemical/enzymatic resistance, as well as good mucoadhesive and oxygen permeability properties [207–209]. However, PVA exhibits some unfavorable mechanical properties (e.g. strength and flexibility), as well as a relatively poor thermal stability [210], though this can be improved by blending PVA with other polymers (including naturally based polymers such as chitosan, gelatin, dextran and hyaluronic acid) [211–213] or by adequate chemical or physical cross-linking [61,208]. Chemical cross-linking can be obtained by using glutaraldehyde, genipin, succinyl chloride, adipoyl chloride and sebacoyl chloride, while physical cross-linking can be obtained by repeated freeze–thawing cycles [61,209,214]. PVA is not chemically or enzymatically degradable in vivo but it may erode quite easily (by dissolution) and thus may not be useful as a long-term or permanent dressing [153].

PVA and its derivatives have already been used as wound dressings for conventional wounds, and have also been tested for diabetic wound treatments [215]. Enhanced healing results were obtained by incorporating NO into the PVA dressing since exogenous NO released increased collagen production, enhanced the quality of the granulation tissue and increased the wound strength. PVA has also been cross-linked with sodium carbamoxymethylcellulose and dextran to improve PVA water (and consequently exude) swelling capacity as well as its water vapor transmission rate. Besides NO, PVA-based dressings have also been loaded with bioactive compounds such as gentamicin and ciprofloxacin since the efficient release of anti-bacterial drugs may help to improve complications in long-term healing [215,216].

3.2.2.2. Poly(ethylene glycol) (PEG)/Poly(ethylene oxide) (PEO). PEG is a polymer which is also known as poly(ethylene oxide) (PEO) or as poly(oxyethylene) (POE), depending on its molecular weight [80]. It is a hydrophilic, biocompatible, flexible, non-toxic and non-immunogenic material that is resistant to protein adsorption and can be synthesized by anionic or cationic polymerization of ethylene oxide [80,153,217].
PVG presents almost all of the favorable and unfavorable properties of PVA when wound dressing applications are envisaged [218]. Furthermore, its terminal hydroxyl groups can be derivatized to create PEG macromers that can participate in other chain or step polymerizations. PEG macromers have low toxicity, and can be coupled with peptides or growth factors and placed in situ to fill irregular sites [80,217]. Three major cross-linking methods have been used to prepare PEG-based hydrogels: radiation of linear or branched PEG polymers [219]; free radical polymerization of PEG acrylates [220]; and other specific chemical reactions, such as condensation reactions [220]. Michael-type additions [221] and enzymatic reactions [222]. PEG acrylates such as PEG diacrylate, PEG dimethacrylate and multiarm PEG (n-PEG)
acrylate are the major types of macromers used for photopolymerization [217].

PEG can also be blended with other polymers such as chitosan, poly(lactic-co-glycolic acid) (PLGA) and poly(propylene fumarate) (PPF) in order to improve its inherent solubility, erosion, mechanical and thermal properties as well as its crystallinity and viscosity [218,223]. The formation of PEG-based block copolymers is also a viable option. PEG-based hydrogels have been used for many biomedical applications including wound dressings [218,224]. In addition, this type of hydrogel has already been demonstrated to be advantageous for diabetic wounds as it promotes proliferation of skin cells, enhanced collagen deposition and reduced scar formation [225–228]. As in the case of the previously discussed materials, PEG has also been associated with other polymers such as PCL, and can be loaded with growth factors such as EGF, bFGF, pdGF or rhGFT which help to increase the wound recovery rate, leading to improved vascularization, enhanced collagen deposition, and maturation and complete re-epithelialization [226,227,229,230].

3.2.2.3. Poly(vinyl pyrrolidone) (PVP). Like PVA and PEG, this hydrophilic and biocompatible material has been extensively used for a wide variety of pharmaceutical and biomedical applications (including wound dressings). This is mostly due to its water absorption and oxygen permeability properties [231,232]. PVP hydrogels can be produced at relatively low cost. This process is simple, safe and efficient [218,233]. Like the two above-described hydrophilic synthetic polymers (i.e. PVA and PEG), PVP is usually blended with other polymers (e.g. agar, cellulose or PEG) or cross-linked with carbodiimides in order to modify its solubility, delivery and erosion profiles, mechanical properties, softness and elasticity [218]. A significant improvement in wound healing of diabetic rats was achieved after application of a new NO delivery platform based on grafting S-nitrosothiolis, derived from endogenous glutathione (GSH) or its oligomeric derivatives, pyrrochelatins, onto poly(vinyl methyl ether co-maleic anhydride) and the subsequent formation of interpolymer complexes with PVP. This complex provides controlled release of NO for more than 10 days, and a single topical application of the NO-controlled delivery system accelerates wound closure as compared with the control [234]. These results suggested that NO-releasing interpolymer complexes could be potentially useful for diabetic wound healing.

3.2.2.4. Polyurethanes (PUs). Polyurethanes are synthesized by condensation and polymerization methods from a wide range of bifunctional or higher-order functional monomers. This will lead to versatile polymeric materials that may present quite different chemical, physical and biological properties [235], such as hydrophilic/hydrophobic characteristics, water sorption, permeation and degradation profiles, as well as thermal and mechanical properties [236]. As an example, PUs can lead to hard, flexible or elastic materials, even without covalent cross-linking [237]. PUs are also non-toxic, sterilizable, non-adherent and non-allergenic [238]. Furthermore, PUs may be easily cross-linked, blended with other synthetic and/or natural-based polymers, and processed in the form of particles, fibers, films, foams and hydrogels [239]. PU-based nanofibers showed controlled evaporative water loss and promoted wound fluid drainage, which are essential characteristics for wound dressing materials [240,241]. When compared to other conventional dressings, some PU-based foam dressings showed higher healing capacities [237,238,241,242]. A dressing constituted of polymeric fibers with repeated units containing urethane groups (aliphatic polyurethane, aromatic polyurethane, aliphatic polyurethane, aromatic polyurethane or a combination of them) was recently patented and presented as effective for the treatment of chronic wounds such as DFUs [237]. The improved capacity to manage wound exudates justifies the regular use of PU-derived materials (mainly in the form of films or foams) in multilayer dressings in order to optimize their healing capacity. As an example, the commercial wound dressing Melioplex® Ag (Molnlycke Health Care, Sweden) comprises a silicone wound contact layer, an absorbent material (polyurethane foam pad), an anti-bacterial (a silver compound, silver sulfate) and a vapor-permeable waterproof film to absorb exudate and to maintain a moist wound environment. It can be used on exuding wounds at risk of infection such as leg ulcers, DFUs, pressure ulcers and burns [243]. As discussed before, PU-based dressings have also been loaded with bioactive compounds to shorten healing periods. A wound dressing containing an antimicrobial therapeutic agent (e.g. penicillin, erythromycin, chlorohexidine, triclosan), a pain-relieving substance (e.g. ibuprofen) and protease inhibitors (e.g. MMP-9, elastase, MMP-8, MMP-12) in a barrier layer made of collagen/poly lactide/polyglycolide or polyurethane was recently patented [238]. This layer breaks down in contact with wounds, releasing the therapeutic substances into the wound. This invention was developed for chronic wound treatment, such as venous ulcers or DFUs. These and other examples are summarized in Table 2.

3.2.2.5. Poly (hydroxyethyl methacrylate) (HEMA). HEMA-based polymers and copolymers are important biocompatible, non-biodegradable materials that can lead to the formation of hydrogels to be employed in various different biomedical and pharmaceutical applications [244]. Their final chemical, physical, sorption and permeability properties will depend on the synthesis method and conditions, on the chemical nature and proportions of the employed co-monomers and cross-linkers, as well as on the final degree of cross-linking [218]. HEMA-based polymers usually present good oxygen permeability, good water sorption and transmission rates, high biocompatibility and non-toxicity [244,245]. HEMA-based hydrogels have been used for artificial skin manufacturing and wound dressing applications [153,218] and many bioactive substances have been incorporated into these materials [153]. An interesting example is the case of a hybrid dressing consisting of a pHEMA core (containing a light-activated NO donor) and a PU coating for use on chronic wounds [246]. One major advantage of this material is the fact that NO release can be controlled by light exposure. The dressing can be illuminated from time to time to deliver NO only to the wound site, maintaining antiseptic conditions. This approach might be superior to simple washing of the affected area with conventional solutions such as hydrogen peroxide.

PHMA and PEG have been combined to develop a hydrogel dressing that can bind covalently to MMP inhibitors and promote the healing of chronic wounds as DFUs. This patented dressing ensures that MMPs in the chronic wound fluid are inhibited (thus reducing their proteolytic content) while guaranteeing that the necessary MMP levels for normal healing are not affected in the wound bed [247].

3.2.2.6. Poly (α-esters) (PLA, PGA, PLGA, PCL). Polylactide (PLA) is one of the most popular aliphatic polyesters since it presents relatively high strength and an appropriate degradation rate for most drug delivery and tissue engineering systems [248]. In fact, PLA possesses good mechanical characteristics, controlled degradation and excellent biocompatibility. However, its strong hydrophobicity limits some of its potential applications [248–250].

Polylactic acid (PLA) is another poly(α-ester) that presents a relatively hydrophilic nature and degrades faster than PLA in aqueous solutions or in vivo. To obtain intermediate degradation rates between PGA and PLA, several copolymers of lactide acid and of glycolic acid poly(lactic-co-glycolic acid) (PLGA) can be synthesized [250,251]. PLA is also a biodegradable polymer with strong biocompatibility, controlled biodegradability and potential for sustained re-
lease of various bioactive substances [252]. Furthermore, it can be processed into many different forms—powder, pellets, fibers, nanoparticles, etc. PLGA microspheres loaded with rhEFG were demonstrated to enhance the growth rate of fibroblasts, and it was also observed that wounds in diabetic rats healed more efficiently than when pure rhEFG is used [252,253].

Dong et al. [252] prepared PLGA microspheres loaded with rhEFG by a solvent-evaporation technique. These microspheres were small in size and presented a high drug encapsulation capacity (~86%). Furthermore, rhEFG-loaded microspheres inserted into the wound site enhanced the growth rate of fibroblasts, and it was also observed that wounds in diabetic rats healed more efficiently than when pure rhEFG is used. Chu et al. [253] used a modified double-emulsion method to prepare rhEFG-loaded PLGA nanoparticles to heal diabetic ulcers. In diabetic rats, these rhEFG-loaded nanoparticles promoted a faster healing rate as well as fibroblast proliferation.

These copolymers can be applied in skin tissue regeneration and suture applications, and have been approved by the FDA for several biomedical and pharmaceutical applications [250]. The incorporation of drugs and other bioactive substances into poly(α-hydroxy acids) has been done with DFU applications in mind. Xu et al. [254] reported the incorporation of a hydrophilic antibiotic drug, tetracycline hydrochloride (TCH), into an electrospun PEG–PLA nanofibrous membrane. This drug-impregnated membrane demonstrated sustained release of TCH over 6 days and was effective at inhibiting growth of Staphylococcus aureus. As observed before for other polymer-based dressings, the loading of growth factors into PLGA-based materials to stimulate the wound healing process is also an option for DFU treatment. As an example, bFGF was embedded into ultrafine PLA fibers with a core–sheet structure [99]. An initially low burst release was achieved, followed by controlled release for around 4 weeks, a profile that is interesting for application in chronic wounds. Results also showed a higher wound recovery rate with complete re-epithelialization, regeneration of skin appendages, higher density and mature capillary vessels in bFGF-loaded scaffolds when compared with fibers without bFGF and after 2 weeks of treatment. Moreover, it also presented enhanced collagen deposition, an ECM remodeling process and components of collagen fibers similar to normal tissues.

Polycaprolactone (PCL) is another biodegradable and biocompatible poly(α-ester) which has been studied for tissue regeneration and wound healing applications since it promotes a faster healing and reduced inflammatory infiltrate [255]. However, PCL degrades at a significantly slower rate than PLA, PGA and PLGA [256]. This slow degradation makes PCL less attractive for this type of biomedical application, but more attractive for sutures, long-term implants and controlled-release applications [250].

Merrel et al. [255] developed PCL nanofibers as a delivery vehicle for curcumin for diabetic wound healing applications [255]. Curcumin is a natural phenolic compound with anti-oxidant and anti-inflammatory properties. The prepared curcumin-loaded nanofibers reduced inflammatory induction from mouse monocyte–macrophages. In addition they increased the rate of wound closure in a STZ-induced diabetic mouse model. These results demonstrated that these curcumin-loaded PCL nanofibers are bioactive and have potential to be applied as wound dressings with anti-oxidant and anti-inflammatory properties for DFU treatment.

4. Future trends and perspectives

DFUs are a frequent complication of diabetes that may lead to severe and persistent infection and, in extreme cases, to lower-extremity amputation. Therapeutics usually involves the use of dressings, aiming to enhance the life quality of DFU patients, to alleviate pain, to deliver drugs and to reduce odors. The necessity to develop and improve the efficacy of wound dressings, particularly suitable for DFU treatment, has been a challenge for both researchers and clinicians. An ideal dressing should confer moisture balance, protease sequestration, growth factor stimulation, antimicrobial activity, oxygen permeability and capacity to promote autolytic debridement that facilitates the production of granulation tissue and the re-epithelialization process. In addition, it should have a prolonged time of action, high efficiency and improved sustained drug release in the case of medicated systems.

New and recent alternatives to conventional dressings have been developed; these include mixing different polymers and using more efficient cross-linking methods to create improved materials that guarantee an optimal wound environment. As discussed, natural (chitosan, hyaluronic acid, cellulose, alginate, collagen, fibrin) or synthetic (PVA, PEG, PVP, PU, PHEMA, poly(α-esters)) polymers have been combined or cross-linked (e.g. with genipin, oxidized dextran or glutaraldehyde) for this purpose. Furthermore, medicated dressings have been examined as a means to efficiently deliver drugs or other bioactive substances that had previously been demonstrated to improve DFU treatment. Dressings loaded with antimicrobials/antibiotics (to decrease infection), platelet-derived substances, patients’ own stem cells, growth factors and peptides act to balance (through up-regulation of growth factors and cytokines and down-regulation of destructive proteolysis) the biochemical events of inflammation in the chronic wound and to improve healing. Some studies dealing with the incorporation of natural extracts showed great potential in the treatment of DFUs; however, these findings do not yet represent a practical option since application of these compounds tends be very expensive and difficult to regulate/control. Therefore, and in the near future, research will certainly focus on the development of more efficient and less expensive biocompatible and biodegradable medicated dressings that can deliver important DFU healing factors to the wound site in order to improve patient care and quality of life.

Acknowledgements

This work was financially supported by COMPETE and Fundação para a Ciência e Tecnologia (FCT-MES) under contracts, PTDC/SAU-BEB/71395/2006, PTDC/SAU-MII/988567/2008, PTDC/SAU-FAR/121109/2010, Pest-C/SAU/LA0001/2011, by EFSDF/JDRF/Novo Nordisk European Programme in Type 1 Diabetes Research and Sociedade Portuguesa de Diabetologia. L.I.F.M. and A.M.A.D. acknowledge FCT-MES for their fellowships SFRH/BD/60837/2009 and SFRH/ BPD/40409/2007, respectively.

Appendix A. Figures with essential colour discrimination

Certain figures in this article, particularly Figures 2 and 3, are difficult to interpret in black and white. The full colour images can be found in the on-line version, at http://dx.doi.org/10.1016/j.actbio.2013.03.033.

References


